Slide 1: Q3 FY24 Investor Presentation
Q3 FY24 Investor Presentation February 2024
Slide 2: Core Values
Biocon is a technology-enabled, future-ready, global biopharmaceuticals leader driven by an unwavering purpose to enhance healthcare worldwide through high- quality, affordable therapies that can lower costs, increase access and improve treatment outcomes. Value Creation through Innovation & Differe
Slide 3: Building Biocon
Building Biocon
Slide 4: Biocon at a Glance
Biocon at a Glance ₹11,550 Cr | ~16,500+ Rank #8 Among Top 10 Global Total Employees* $ ~1.4 bn Biotech, Pharma & Revenue* Biopharma Sector** 1,500+ 100+ 8 Patents* cGMP approvals from International regulatory agencies Manufacturing units* 120+ 15 of top 20 Top 28 Countries where our pharma companie
Slide 5: Biocon: One Company, with multiple value propositions across its verticals
Biocon: One Company, with multiple value propositions across its verticals From pipeline to production, from drug discovery to drug delivery, we bring differentiated, high-quality & affordable healthcare products & services, globally Ensuring access through quality, affordability, reliability ▪ Lead
Slide 6: Generics Business at a Glance
Generics Business at a Glance Presence in R&D team of 7 90+ 750+ 100+ State-of-the-art cGMP approvals 500+ countries including U.S., manufacturing received from international Scientists & Global Europe & large EMs sites regulatory agencies Postgraduates customer reach Portfolio comprises 100+ 500+ 3
Slide 7: Generics: API & Formulations - Growth Levers
Generics : API & Formulations - Growth Levers Strengths built over the years Product Portfolio Expansion Capacities Additions & Expansion • Expertise in fermentation technology, large scale • API - Expanding portfolio beyond fermentation and • Immunosuppressants API (Visakhapatnam) chromatography &
Slide 8: Generics: Our Key APIs and Formulations
Generics : Our Key APIs and Formulations APIs* F O R M U L AT I O N S Therapeutic Area Molecule US Dev. Markets: ex-US MoW1 Therapeutic Area Molecule Therapeutic Area Molecule Rosuvastatin Calcium EU Simvastatin Apixaban Tacrolimus Atorvastatin Mycophenolate Atorvastatin Cardiovascular Pravastatin M
Slide 9: Biosimilars Business at a Glance
Biosimilars Business at a Glance Global reach in Diverse global Top 15 85+ 100+ in global cGMP approvals talent pool of countries including U.S., biomanufacturing received from key regulatory 5,500+ Europe and EMs capacity agencies people 390+ Portfolio comprises 8 patents granted 20 biosimilars Com
Slide 10: Biosimilars: Unique, fully integrated capabilities from lab to market
Biosimilars: Unique, fully integrated capabilities from lab to market Research & Development Global Scale Manufacturing Commercialization Process & Product Development Mammalian & microbial tech platforms Commercial footprint in 100+ countries 3 Manufacturing Sites Analytical & Bioanalytical Capabil
Slide 11: Biosimilars: Leading global player with a strong track record of success
Biosimilars: Leading global player with a strong track record of success Built on a 40+ year legacy of cutting-edge science …with a strong track record in an attractive market • Invested >$1B in biosimilars ahead of its peers to build • Achieved many ‘firsts’ in the industry - first to receive exper
Slide 12: Biosimilars: Acquisition of Viatris' global biosimilars business
Biosimilars: Acquisition of Viatris’ global biosimilars business Provides full Accelerates BBL’s ownership direct entry in of collaboration many markets assets, as well as across AMs & EMs, Viatris’ rights for in- takes us closer to licensed biosimilars USD 3B+ Acquisition - Amongst Largest patients
Slide 13: Biosimilars: Comprehensive, industry leading portfolio of 20 biosimilars
Biosimilars: Comprehensive, industry leading portfolio of 20 biosimilars Oncology Immunology Ophthalmology Bone Health Diabetes Others Therapy Area • Pegfilgrastim • Adalimumab • Aflibercept • RHI Approved or • Trastuzumab • Etanercept • Glargine U100 Commercial • Bevacizumab • Aspart • Denosumab •
Slide 14: Novel Molecules: Itolizumab
Novel Molecules: Itolizumab Pushing to deliver impactful innovations in collaboration with Equillium Inc. ✓ Pivotal Phase III Study initiated in Apr ’22 for use in First-Line treatment of aGVHD; enrollment Acute Graft- ongoing Itolizumab Versus-Host ✓ Received US FDA Fast Track & Orphan Drug Designa
Slide 15: Novel Molecules: Bicara Therapeutics - BCA101
Novel Molecules: Bicara Therapeutics* - Dual Action | Dual Impact The precision of targeted therapies | The power of tumor modulators ✓ Lead product candidate, BCA101 (EGFR / TGF-β-trap) demonstrates tumor target engagement and clinical activity ✓ BCA101 + pembrolizumab combination dose expansion st
Slide 16: Syngene's broad capabilities spanning the value chain
Syngene’s broad capabilities, spanning the value chain, facilitate integration to captures additional benefits for clients Research business Development and Manufacturing business Discovery Services Dedicated R&D Centers Development Services Manufacturing Services Flexible Platform with capability a
Slide 17: Syngene: Strategic Priorities
Syngene: Strategic Priorities Research: Research: Discovery Services Dedicated Centers Operational Excellence Provide end-to-end therapeutic Continue to strengthen our existing Focus on customer delivery discovery capabilities including partnerships with Amgen, Bristol through operational excellence
Slide 18: Q3 FY24 Highlights
Q3 FY24 Highlights
Slide 19: Financial Highlights: Q3 FY24
Financial Highlights: Q3 FY24 Consolidated (in ₹ Cr.) Q3 FY24 Q3 FY23 YoY % Total Revenue1 4,519 3,020 50 Biosimilars +65% | Research +9% | Generics -7% Core EBITDA2 983 1,069 (8) % Margin 27% 36% Net R&D spend at ₹329 Cr, representing 11% of EBITDA 1,492 723 106 revenues ex-Syngene % Margin 33% 24%
Slide 20: Financial Highlights: Q3 FY24 - Exceptional Items
Financial Highlights: Q3 FY24 Consolidated (in ₹ Cr.) Q3 FY24 Q3 FY23 YoY % Net Profit 644 140 360 (Before exceptional items) Exceptional items: • Q3 FY24 • Gain on carrying value of existing contractual receivable arrangement; offset by Exceptional Items • Impairment of intangibles associated with
Slide 21: Biocon Generics: Q3 FY24 Highlights
Biocon Generics: Q3 FY24 Highlights Q3 Q3 Q2 YoY QoQ In INR Cr FY24 FY23 FY24 % % Consistent steady/ growth in Generic Formulations business Segment Revenue 703 760 676 (7) 4 Received first Generic Formulation approval in China, for Mycophenolate Core EBITDA 154 168 158 (8) 2 Sodium % of revenue 22%
Slide 22: Biocon Biologics: Biosimilars – Q3 FY24 Business Update
Biocon Biologics: Biosimilars – Q3 FY24 Business Update Key Products’ Market Share1 United States Finished operational integration of acquired business from Viatris in Nov-23 Aug-23 Nov-22 about 120 countries, one year ahead of schedule Fulphila (bPegfilgrastim) 18% 20% 11% Ogivri (bTrastuzumab) 12%
Slide 23: Biocon Biologics: Biosimilars – Q3 FY24 Financial Update
Biocon Biologics: Biosimilars – Q3 FY24 Financial Update Q3 Q3 Q2 In INR Cr YoY % QoQ % FY24 FY23 FY24 Excluding licensing revenues from the non-core BFI divesture, Segment Revenue 2,483 1,507 1,969 65 26 sequential growth of 8% Core EBITDA1 587 663 660 (11) (11) Core EBITDA margin impacted on accou
Slide 24: Biocon Biologics: Biosimilars – Q3 FY24 Other Business Updates
Biocon Biologics: Biosimilars – Q3 FY24 Other Business Updates Initiated Phase 3 studies for bPertuzumab Progressive discussion with the US FDA ; Awaiting site-inspection for bAspart and bBevacizumab BLA in US Key Catalysts Opening up of bAdalimumab market along with regulatory approvals for bAspart
Slide 25: Novels: Q3 FY24 Update
Novels : Q3 FY24 Update Itolizumab (partnered with Equillium) Patient enrolment ramped up in the pivotal Phase III clinical study of itolizumab in patients with aGVHD* (EQUATOR study) Pivotal Phase 1b clinical study of Itolizumab for Lupus Nephritis (EQUALISE study) fully enrolled. Topline data expe
Slide 26: Syngene: Q3 FY24 Update
Syngene: Q3 FY24 Update Positive performance in Development and Manufacturing Services as well In INR Cr Q3 FY24 Q3 FY23 YoY % as in the Dedicated Centers. Performance in Discovery Services was impacted by the slowdown in biotech funding Segment Revenue 854 786 9 EBITDA 261 248 5 In Manufacturing Se
Slide 27: Environment, Social, Governance
Environment, Social, Governance
Slide 28: ESG: A Culture of Purpose, Ethics & Equity
ESG: A Culture of Purpose, Ethics & Equity Disclosures and Going beyond financials to have a positive impact Recognitions Published 1st GRI aligned Our ESG Strategy Pillars Integrated Report & 2nd BRSR Report for FY23 Improved ESG score of Improve access to high quality therapeutics to drive ‘Patien
Slide 29: Progressed to Integrated Reporting
Progressed to Integrated Reporting Continuously improving disclosures towards better transparency 1st GRI aligned Integrated Report for FY23 with many maiden disclosures Outcome of Gender Pay Gap Analysis Alignment with TCFD Outcome of Water Risk Assessment Outcome of Biodiversity Impact Assessment
Slide 30: Annexures
Annexures
Slide 31: Our Evolution Over the Years
Our Evolution Over the Years 1978 2000 2005 2010 2019 to to to to & 1999 2004 2009 2018 beyond An Transforming Building the Base Building Scale Poised for Global Enzymes into a Biopharma Business and for Global Impact Impact: Biosimilars, Company Company Expertise in Biologics Generic Formulations S
Slide 32: With many firsts, Biocon is ahead of the curve
With many firsts, Biocon is ahead of the curve 2000 2006 2016 2019 1993 to to to & 2004 2015 2018 beyond ISO 9001 Certification Established Launched Biosimilar approved bGlargine for a Life Science Clinigene –Clinical Nimotuzumab, novel in Japan (bGlargine) commercialized in Company Research Service
Slide 33: Safe Harbor Statement
Safe Harbor Statement This release may include statements of future expectations and other forward-looking statements based on management's current expectations and beliefs concerning future developments and their potential effects upon Biocon and its subsidiaries/ associates. These forward-looking
Slide 34: Thank You
Thank You $ Biocon 4 on iS hares @> ye. Rote re Oc ee ee oe tet oe, ete e ra sly . we ee wt “ete eS. Cy “ : Aw** Relentless Pursuit. Differentiated Growth. O~» 34